Evidence map›Paper›PMID 42824818›Full record

ArticleAntibody therapeutics2026

Efficacy of IgY on

Zahra Esmaeili, Sara Kamal Shahsavar, Elham Khosravi, Hamid Ariannejad, Mohammadreza Nassiri, Ali Beheshti Namdar, Mitra Ahadi, Ramin Sadeghi, Vahid Reza Dabbagh, Faezeh Sabet Birjandi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibody therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zahra EsmaeiliDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.ORCID https://orcid.org/0000-0002-6098-7471
Sara Kamal ShahsavarDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Elham KhosraviDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Hamid AriannejadDepartment of Biotechnology, Ferdowsi University of Mashhad, Mashhad, 9177948974, Iran.
Mohammadreza NassiriDepartment of Agriculture, Ferdowsi University of Mashhad, Mashhad, 9177948978, Iran.
Ali Beheshti NamdarDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 91778 99191, Iran.
Mitra AhadiDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 91778 99191, Iran.
Ramin SadeghiDepartment of Nuclear Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Vahid Reza DabbaghDepartment of Nuclear Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Faezeh Sabet BirjandiDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Majid Khadem RezaiyanDepartment of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 913791-3316, Iran.
Kiarash GhazviniDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.ORCID https://orcid.org/0000-0002-8538-1425

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: In this randomized, double-blind trial, 60 patients with confirmed Results: Baseline demographic characteristics were homogeneous. The median urea breath test value in the intervention group decreased from 77 to 11, whereas that of the control group remained unchanged (median = 55). Bacterial eradication was achieved in 33.3% of IgY recipients versus 13.3% of controls (difference, 20%; Conclusion: Clinical symptoms showed trends toward faster improvement, but these did not reach statistical significance. IgY may be a promising safe adjunct for the treatment of

Indexed as

clinical trialH. Pyloriimmunoglobulin Ysymptom assessment

Identifiers

PMID42824818
PMCPMC13628135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.